Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM On Twitter
  • JABFM On YouTube
  • JABFM On Facebook
ReplyCorrespondence

Response: Re: Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED)

Adriane Fugh-Berman and Jin Jung
The Journal of the American Board of Family Medicine September 2020, 33 (5) 816-818; DOI: https://doi.org/10.3122/jabfm.2020.05.200373
Adriane Fugh-Berman
Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ajf29@georgetown.edu
Jin Jung
Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ajf29@georgetown.edu
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

To the Editor: No one disputes that drug companies provide educational grants for continuing medical education (CME); as the largest CME provider in the country, Medscape receives substantial funds from industry. In this case, all 3 Medscape activities1⇓–3 were funded by Shire.

Medscape's modules on binge-eating disorder (BED) contain many marketing messages, including linking BED to obesity, and linking lisdexamfetamine with weight loss. Omissions are important, too: not one of Medscape's modules mention that lisdexamfetamine, like other amphetamines, has a high potential for abuse, and other serious harms including stroke and sudden death.

Medscape's CME activities specifically link obesity with BED; stating, for example, “Anyone who presents with weight concerns should be asked about binge eating.”1 The correct answer to 1 test question is “Most people with obesity demonstrate binge-eating behavior.”2 Another test question asked: “Mary, a 36-year-old woman, comes to your office with complaints of a “sore back.” She stands 5 ft 6 in tall and weighs 265 lb. A radiograph reveals no disc or vertebral problems. You are concerned that her sore back may be due to her weight. Which of the following is the most appropriate treatment approach?”1,4

The correct answer is, “Ask, in the privacy of the examination room, if she has trouble with binge eating.”4 The far more rational answer, “Emphasize that she is obese and should go on a strict diet and exercise regimen” is deemed incorrect.

Medscape's statement that its Shire-funded activities cannot be industry influenced because they “were developed before availability of phase 3 data” simply proves our point that CME is used as marketing years before a drug is approved. Before the approval of Vyvanse, a Medscape activity promoted Shire's drug, stating, “Lisdexamfetamine dimestylate, which is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), is being investigated as a potential treatment for BED.”1 Another preapproval activity links lisdexamfetamine with weight loss: “Although a change in weight was not an outcome, it was monitored as a safety variable and weight loss was documented with lisdexamfetamine as opposed to placebo” and implies an advantage over other drugs: “…although selective serotonin reuptake inhibitors (SSRIs) are modestly effective for reducing binge eating, they are usually not associated with clinically significant weight loss.”2

Despite this endorsement via CME, the label for Vyvanse (approved in 2015 as the first drug for BED), specifically contraindicates its use for weight loss.5

After lisdexamfetamine was approved, Medscape released another Shire-funded CME, called Test Your Knowledge of Challenging Cases in Eating Disorders.6 It is a perfect example of the use of CME to promote a drug and conduct market research. Shire paid Medscape not only for creating CME but for analyzing its impact. Market research analyses allow a company to see how effective a program is: Will it increase diagnoses of the targeted condition? Will it increase prescribing of the targeted drug?

Two of the 4 CME questions for this activity recommend lisdexamfetamine. The market research report shows that before taking this CME activity, 40% of the physicians said they would choose to continue prescribing lisdexamfetamine for BED in a particular patient vignette. When presented with the same situation again at the end of the program, 82% said they would continue lisdexamfetamine.7 A doubling in intent to prescribe is a sizable return on investment.

Leslie Citrome, MD, MPH, served as a faculty member for the CME program6 and also coauthored the market research report.7 Medscape's use of faculty members for both education and marketing may be inconsistent with Food and Drug Administration's Guidance on Industry Supported Scientific and Educational Activities.8

Unfortunately, such use does not violate Accreditation Council for Continuing Medical Education (ACCME) standards. Not only does ACCME allow industry-paid physicians and industry employees to provide CME, but it hides and distorts the amount of money industry spends on CME.9 ACCME makes no real attempt to exclude commercial bias in the activities they accredit.

The fact that Medscape reviewers found content to be free of bias means nothing. Commercially biased activities are designed not to raise suspicion. Qualitative research techniques can be used to identify bias. My research team has pioneered the reverse engineering of marketing messages in CME; we have documented promotional messages in CME activities on hypoactive sexual desire disorder,10 chronic noncancer pain,11 and BED.12 Our studies — and every other study on marketing messages or changes in prescribing behavior related to industry-funded CME13⇓–15 — have found commercial bias, because, well, it is almost always there.

In short, both the qualitative methods we have pioneered to assess marketing in CME, and the quantitative methods Medscape itself uses, show that CME is a marketing tool for pharmaceutical companies. Industry-funded CME serves industry, not physicians, patients, or society.

Notes

  • To see this article online, please go to: http://jabfm.org/content/33/5/816.full.

References

  1. 1.↵
    1. Bulik CM,
    2. Keck PE,
    3. McElroy SL,
    4. Vega CP
    . Recent advances in the management of binge eating disorder. March 26, 2014. Available from: https://www.medscape.org/viewarticle/821956?src=wnl_cme_revw.
  2. 2.↵
    1. McElroy SL
    . Assessing the impact of binge eating disorder: focus on your practice. December 26, 2013. http://www.medscape.org/viewarticle/818103.
  3. 3.↵
    1. McElroy SL,
    2. Vega CP
    . Improving the management of binge eating disorder: a collaborative treatment approach. September 2, 2014. Available from: http://www.medscape.org/viewarticle/830450_transcript.
  4. 4.↵
    1. Spyropoulos J,
    2. Chatterjee P,
    3. Desai J,
    4. Vega C
    . Effectiveness of online CME in improving knowledge and awareness related to emerging management approaches for binge-eating disorder (poster). Available from: https://img.medscapestatic.com/pi/edu/qrcode/posters/effectiveness-of-online-cme-for-binge-eating-disorder.pdf Accessed July 8, 2020.
  5. 5.↵
    Vyvanse. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf.
  6. 6.↵
    1. Citrome L
    . Test your knowledge of challenging cases in eating disorders. February 23, 2016. Available from: https://www.medscape.org/viewarticle/855587.
  7. 7.↵
    1. Lubarda J,
    2. Chatterjee P,
    3. Citrome L
    . Binge eating disorder management: can medical education improve physician knowledge? (poster). Available from: https://img.medscapestatic.com/pi/edu/qrcode/posters/binge-eating-disorder-management-can-medical-education-improve-physician-knowledge.pdf. Accessed July 8, 2020.
  8. 8.↵
    FDA Guidance document: industry-supported scientific and educational activities. December 1997. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/industry-supported-scientific-and-educational-activites. Accessed July 10, 2020.
  9. 9.↵
    1. Fugh-Berman A,
    2. Hogenmiller A
    . CME stands for commercial medical education: and ACCME still won't address the issue. J Med Ethics 2016;42:172–3.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Meixel A,
    2. Yanchar E,
    3. Fugh-Berman A
    . Hypoactive sexual desire disorder: inventing a disease to sell low libido. J Med Ethics 2015;41:859–62.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Infeld M,
    2. Bell A,
    3. Marlin C,
    4. et al
    . Continuing medical education and the marketing of fentanyl for breakthrough pain: marketing messages in an industry‐funded CME module on breakthrough pain. World Med Health Pol 2019;11:43–58.
    OpenUrl
  12. 12.↵
    1. Jung J,
    2. Fug-Berman A
    . Marketing messages in continuing medical education (CME) modules on binge-eating disorder (BED). J Am Board Fam Med 2020;33:240–51.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Dieperink ML,
    2. Drogemuller L
    . Industry-sponsored grand rounds and prescribing behavior. JAMA 2001;285:1443–4.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Orlowski JP,
    2. Wateska L
    . The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992;102:270–3.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Bowman MA,
    2. Pearle DL
    . Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof 1988;8:13–20.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 33 (5)
The Journal of the American Board of Family Medicine
Vol. 33, Issue 5
September/October 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Response: Re: Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED)
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
15 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Response: Re: Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED)
Adriane Fugh-Berman, Jin Jung
The Journal of the American Board of Family Medicine Sep 2020, 33 (5) 816-818; DOI: 10.3122/jabfm.2020.05.200373

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Response: Re: Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED)
Adriane Fugh-Berman, Jin Jung
The Journal of the American Board of Family Medicine Sep 2020, 33 (5) 816-818; DOI: 10.3122/jabfm.2020.05.200373
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Notes
    • References
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • An Approach to Hair Loss in Hijab-Wearing Individuals in Primary Care
  • Re: Impact of Geodemographic Factors on Antibiotic Prescribing for Acute, Uncomplicated Bronchitis or Upper Respiratory Tract Infection
  • Re: Diversity of Department Chairs in Family Medicine at US Medical Schools
Show more Correspondence

Similar Articles

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2023 American Board of Family Medicine

Powered by HighWire